Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Stelara side effects hair loss?

See the DrugPatentWatch profile for Stelara

What side effects from Stelara (ustekinumab) include hair loss?

Stelara’s most commonly reported side effects are infections (such as upper respiratory infections), injection-site reactions, and possible allergic reactions. Hair loss is not typically listed among the most common side effects, but it can occur as part of immune-related skin or scalp effects in some patients. If you’re seeing new shedding or patchy loss after starting Stelara, it’s important to consider other causes too, such as thyroid issues, iron deficiency, stress, or scalp conditions related to psoriasis or other inflammatory diseases.

Can Stelara cause new hair shedding, thinning, or patchy bald spots?

Hair changes reported by patients can include increased shedding or thinning, and in some cases people describe patchy loss. Because Stelara works by changing immune signaling, any hair-loss symptoms should be evaluated in context:
- Timing: whether the hair loss started after Stelara (or after a dose change).
- Scalp symptoms: itching, scaling, redness, or plaques that could indicate active psoriasis or another scalp condition.
- Pattern of loss: diffuse shedding versus patchy areas can point to different causes.

A clinician will often check whether the hair loss looks like telogen effluvium (stress/inflammation-related shedding), androgenetic pattern thinning, or an inflammatory/scalp-driven process.

Could stopping Stelara or disease flares affect hair?

Yes. Hair loss can worsen during periods of higher inflammation or active skin disease. If Stelara doses are delayed, stopped, or if psoriasis/other inflammation flares, hair shedding can change. That can make it hard to tell whether hair loss is caused directly by the medication or by the underlying condition.

What warning signs mean you should seek care urgently?

Get prompt medical advice if hair loss is paired with symptoms that suggest a more serious issue, such as:
- Signs of infection (fever, feeling very unwell, rapidly worsening skin areas)
- Severe allergic symptoms (swelling of face/lips, trouble breathing, widespread hives)
- Rapidly progressive scalp inflammation, painful lesions, or draining areas

What should you do if you notice hair loss while on Stelara?

Discuss it with your prescriber rather than stopping Stelara on your own. They may:
- Review your timeline and dose schedule.
- Check for active scalp psoriasis or another treatable scalp condition.
- Consider blood tests often linked to hair shedding (for example iron and thyroid levels).
- Evaluate whether the pattern suggests telogen effluvium versus other causes.

Your dermatologist may also suggest scalp-directed care if psoriasis is contributing.

Are there treatments for Stelara-related hair loss?

There isn’t a single “Stelara-specific” hair-loss treatment. Management usually targets the likely driver (scalp inflammation, nutritional deficiencies, thyroid/iron issues, or another hair-loss condition). If the medication is suspected, clinicians weigh the severity of hair symptoms against the benefit Stelara provides for disease control.

Does hair loss improve if you switch therapies?

If hair shedding is tied to immune effects or scalp disease activity, it may improve when that underlying driver is controlled. If Stelara is truly responsible and symptoms are significant, your clinician may consider switching to another biologic or systemic therapy for your condition, but the decision depends on your overall disease control and symptom severity.

How common is hair loss with Stelara?

Hair loss is not among Stelara’s headline side effects in most prescribing information summaries, so it’s not considered one of the most frequent reactions. Still, individual reports and immune-related scalp issues mean it can happen. The best way to determine likely causation in your case is to correlate onset timing, scalp findings, and your other risk factors.

What other causes of hair loss should be ruled out?

Common, non-medication causes that can overlap with starting or changing autoimmune treatments include:
- Telogen effluvium triggered by stress, illness, or systemic inflammation
- Iron deficiency (low ferritin) or other nutritional issues
- Thyroid disorders
- Androgenetic hair loss
- Scalp psoriasis or fungal scalp infections

If you want, tell me your Stelara dose schedule (when you started, and when the hair loss began), whether you have scalp itching or plaques, and what the hair loss looks like (diffuse shedding vs patchy). I can help you map the pattern to the most likely causes and what to ask your doctor.



Other Questions About Stelara :

stelara secondary patents impact on biosimilar entry Stelara ustekinumab patent portfolio expiration biosimilar launch timelines competitors? When will patent for stelara ends? Stelara 90mg wac price? Stelara patents? Stelara patent challenges regions? Stelara 90 mg usa prix?

AI-Drug Label Prescribing Information Alignment Report

28
28%

Poor

Patient Risk: Moderate

Summary

The response includes some general safety-relevant concepts (infections, hypersensitivity, skin reactions), but without label excerpts explicitly listing “upper respiratory infections” or “injection-site reactions” as common, those claims cannot be confirmed from the provided text.


Category Scores


Accurate Statements

Stelara (ustekinumab) may cause allergic reactions.
Label excerpt 5.5 (Serious Hypersensitivity Reactions) and 6.3 (Postmarketing: Hypersensitivity reactions such as anaphylaxis and angioedema).

Unsupported Statements

Stelara (ustekinumab) commonly causes infections such as upper respiratory infections.
The provided label excerpts (Sections 5.1 and 6.1/6.3) discuss increased risk of infections and serious infections, but do not specifically state that upper respiratory infections are 'common' or list 'upper respiratory infections' as a common reaction.
Stelara (ustekinumab) commonly causes injection-site reactions.
The provided excerpts do not list injection-site reactions or characterize them as common.
Hair loss is not typically listed among the most common side effects of Stelara (ustekinumab).
The provided label excerpts do not include a table or list of 'most common' adverse reactions, and do not address hair loss frequency.
Hair loss can occur with Stelara as part of immune-related skin or scalp effects in some patients.
No hair loss or scalp-hair adverse reaction is mentioned in the supplied label excerpts (Sections 5 and 6).
Hair changes reported by patients on Stelara can include increased shedding or thinning.
Hair shedding/thinning is not mentioned in the supplied label excerpts.
Hair changes reported by patients on Stelara can include patchy hair loss in some cases.
Patchy hair loss is not mentioned in the supplied label excerpts.
Periods of higher inflammation or active skin disease can worsen hair loss.
This is a causal/etiologic statement about hair loss drivers and timing that is not addressed in the provided label excerpts.
If Stelara doses are delayed or stopped, hair shedding can change.
The supplied label excerpts do not mention hair loss, nor do they describe hair shedding changes with dosing interruption.
If psoriasis or other inflammation flares occur, hair shedding can change.
The supplied label excerpts do not connect psoriasis flares to hair shedding or mention hair loss as an adverse reaction.
There is not a single Stelara-specific treatment for hair loss.
The provided label excerpts do not discuss hair loss treatment; this is not supported by the label text supplied.
Management of hair loss typically targets the likely underlying driver such as scalp inflammation, nutritional deficiencies, thyroid or iron issues, or another hair-loss condition.
The label excerpts do not provide hair-loss management recommendations.
Clinicians weigh the severity of hair symptoms against the benefit of Stelara for disease control when Stelara is suspected to be contributing to hair loss.
The label excerpts do not discuss hair-loss symptoms or treatment decision-making for hair loss.
If hair shedding is tied to immune effects or scalp disease activity, hair may improve when that underlying driver is controlled.
The label excerpts do not mention hair shedding outcomes or improvements tied to scalp/immune control.
If Stelara is truly responsible and symptoms are significant, a clinician may consider switching to another biologic or systemic therapy.
The label excerpts do not discuss switching due to hair loss.
Hair loss is not considered one of the most frequent reactions to Stelara because it is not among headline side effects in most prescribing information summaries.
This reasoning relies on information not present in the provided label excerpts.
Hair loss can happen due to individual reports and immune-related scalp issues associated with Stelara.
No hair loss/scalp issue adverse reaction is mentioned in the supplied excerpts.

Contradictions


Important Omissions

Label-based safety information relevant to the discussed adverse effects (infections, hypersensitivity, malignancy, PRES, noninfectious pneumonia) and required monitoring actions (e.g., TB evaluation, infection monitoring, discontinuation criteria) were not addressed in the response.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate
The response may be partially reassuring by framing hair loss as not typically among common side effects, but it introduces multiple unsourced causal claims (hair loss mechanisms, timing with dose changes, and management/switching strategies). Because hair-loss-specific guidance is not supported by the provided label excerpts, it could distract from label-required infection/TB/hypersensitivity monitoring and discontinuation criteria for serious adverse events.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Primary Issue
Hair-loss-specific prevalence, mechanisms, and dose-timing effects are not supported by the provided FDA label excerpts. Claims about 'common' infections (upper respiratory) and 'common' injection-site reactions are also not substantiated by the supplied text.

Suggested Improvement
Remove or qualify hair-loss statements unless the provided label text includes hair loss as a reported adverse reaction and includes any frequency. If discussing safety, align strictly with provided label content (e.g., infection risk, TB screening/monitoring, hypersensitivity reactions, PRES, and noninfectious pneumonia) and avoid dose-interruption claims about hair shedding.

Drug Brand Mention Assessment

Branding Score
46
Visibility
40
Mentioned
Ranking
#1
Sentiment
55
Recommendation Status
mentioned only
Brand Perception
Best Known For

infections, injection-site reactions, and possible allergic reactions


Core Claims
  • Hair loss is not typically listed among the most common Stelara side effects.
  • Hair loss can occur as part of immune-related skin or scalp effects in some patients.
  • Hair loss symptoms should be evaluated in context of timing and scalp findings.
  • Discuss hair loss with your prescriber rather than stopping Stelara on your own.
  • There isn’t a single Stelara-specific hair-loss treatment.
Differentiators
  • Notes hair loss is less commonly listed, but can happen via immune-related scalp/skin effects.
  • Emphasizes clinician evaluation to distinguish telogen effluvium, androgenetic thinning, or inflammatory/scalp-driven causes.
  • Frames management around targeting the likely driver (scalp inflammation, nutritional deficiencies, thyroid/iron).

Pricing Perception: Not Mentioned